172 related articles for article (PubMed ID: 38246181)
1. [Research progress on immunotherapy based on NK cells for hepatocellular carcinoma].
Zhu X; Zhou Y; Zhu S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Jan; 40(1):80-88. PubMed ID: 38246181
[TBL] [Abstract][Full Text] [Related]
2. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.
Sun C; Sun H; Zhang C; Tian Z
Cell Mol Immunol; 2015 May; 12(3):292-302. PubMed ID: 25308752
[TBL] [Abstract][Full Text] [Related]
3. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review.
Schoenberg MB; Li X; Li X; Han Y; Börner N; Koch D; Guba MO; Werner J; Bazhin AV
Int Immunopharmacol; 2021 Dec; 101(Pt A):108220. PubMed ID: 34673334
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
[TBL] [Abstract][Full Text] [Related]
5. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z
Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014
[TBL] [Abstract][Full Text] [Related]
6. Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications.
Sung PS; Jang JW
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30463262
[TBL] [Abstract][Full Text] [Related]
7. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy.
Liu P; Chen L; Zhang H
J Immunol Res; 2018; 2018():1206737. PubMed ID: 30255103
[TBL] [Abstract][Full Text] [Related]
8. Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma.
Zhuang L; Fulton RJ; Rettman P; Sayan AE; Coad J; Al-Shamkhani A; Khakoo SI
Hepatol Int; 2019 Jan; 13(1):75-83. PubMed ID: 30467624
[TBL] [Abstract][Full Text] [Related]
9. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
Bozward AG; Warricker F; Oo YH; Khakoo SI
Front Immunol; 2021; 12():643310. PubMed ID: 33995362
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
11. Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS-STING pathway in hepatocellular carcinoma.
Xu Y; Sun F; Tian Y; Zeng G; Lei G; Bai Z; Wang Y; Ge X; Wang J; Xiao C; Wang Z; Hu M; Song J; Yang P; Liu R
Int Immunopharmacol; 2024 Mar; 129():111628. PubMed ID: 38320351
[TBL] [Abstract][Full Text] [Related]
12. Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma.
Nishida S; Levi DM; Tzakis AG
Curr Opin Organ Transplant; 2013 Dec; 18(6):690-4. PubMed ID: 24220052
[TBL] [Abstract][Full Text] [Related]
13. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
14. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
15. Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma.
Ohira M; Nishida S; Tryphonopoulos P; Tekin A; Selvaggi G; Moon J; Levi D; Ricordi C; Ishiyama K; Tanaka Y; Ohdan H; Tzakis AG
Cell Transplant; 2012; 21(7):1397-406. PubMed ID: 22469170
[TBL] [Abstract][Full Text] [Related]
16. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.
Kalathil SG; Thanavala Y
Cells; 2021 May; 10(6):. PubMed ID: 34071188
[TBL] [Abstract][Full Text] [Related]
17. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
Ghaedrahmati F; Esmaeil N; Abbaspour M
Cancer Commun (Lond); 2023 Feb; 43(2):177-213. PubMed ID: 36585761
[TBL] [Abstract][Full Text] [Related]
18. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
19. CNOT7 depletion reverses natural killer cell resistance by modulating the tumor immune microenvironment of hepatocellular carcinoma.
Ren C; Ren X; Cao D; Zhao H; Zhai Z; Li H; Li Y; Fu X; He J; Zhao H
FEBS Open Bio; 2020 May; 10(5):847-860. PubMed ID: 32160402
[TBL] [Abstract][Full Text] [Related]
20. NK cell marker gene-based model shows good predictive ability in prognosis and response to immunotherapies in hepatocellular carcinoma.
Li J; Li Y; Li F; Xu L
Sci Rep; 2023 May; 13(1):7294. PubMed ID: 37147523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
